MODULE 2

Repurposing Diabetes Drugs in Heart Failure:
What Cardiologists Need to Know





Self-Assessment Program

Step 1: Watch the video

Step 2: Test your knowledge

Step 3: Complete the evaluation form

Step 4: Receive your certificate





X FACULTY

Chair:

Eileen O’Meara
MD, FRCPC

Cardiologist, Montreal Heart Institute
Professor of Medicine,
Université de Montréal
Montreal, QC, Caanda



Members:

Elizabeth Swiggum
MD, FRCPC, FCCS

Medical Director, Heart Function Clinic/Cardiac Rehabilitation, Royal Jubilee Hospital
Clinical Associate Professor, University of British Columbia
Board member, Canadian Heart Failure Society
Medical Chair, Heart Failure and Chronic Cardiovascular Disease, CSBC
Victoria, BC, Canada



 

Jean-François Yale
MD, CSPQ, FRCPC

Professor of Endocrinology, McGill University Health Centre, Montreal
Montreal, QC, Canada



X COMPLETE BIO

Eileen O’Meara

MD, FRCPC

Cardiologist, Montreal Heart Institute
Professor of Medicine,
Université de Montréal
Montreal, QC, Caanda


Dr. Eileen O’Meara is an Associate Professor at the Department of Medicine at the Université de Montréal and practices cardiology at the Montreal Heart Institute. She pursued a Fellowship in Heart Failure at the Western Infirmary & Glasgow Royal Infirmary in the UK (2003-2004), and another in Stress Echocardiography and Tissue Doppler at Hôpital Européen Georges Pompidou in Paris (2004-2005). From 2007 to 2010, Dr. O’Meara oversaw resident training/ teaching at the Montreal Heart Institute’s Echocardiography Laboratory. She is a member of the Internal Review Board for Research at the Montreal Heart Institute and, in 2018, she became the Chief of Outpatients Clinics at MHI.

Dr. O’Meara is a Fellow of the Royal College of Physicians of Canada and a member of multiple cardiology associations. She is currently Co-Chair of the Primary Panel for the CCC Heart Failure Guidelines. She is a Reviewer for the Canadian Journal of Cardiology, the European Heart Journal, the European Journal of Heart Failure, Circulation and Circulation: Heart Failure, and the Journal of Cardiac Failure, among others, and does abstract grading for the European Society of Cardiology and CCC meetings.

Her research focuses on remodeling and fibrosis biomarkers in HF, including cardiac imaging biomarkers; as well as on comorbid conditions that contribute to HF, including diabetes, CKD and anemia. Dr. O’Meara is the Canadian leader of the soon to be published PARAGON-HF trial, evaluating the role of sacubitril/ valsartan in HF with preserved EF. She is also a national leader for the DAPA- HF and DELIVER trials, as well as a member of the Steering Committees for the GALACTIC-HF trial and the HEART-FID trial.

X COMPLETE BIO

Elizabeth Swiggum

MD, FRCPC, FCCS

Medical Director, Heart Function Clinic/Cardiac Rehabilitation, Royal Jubilee Hospital
Clinical Associate Professor, University of British Columbia
Board member, Canadian Heart Failure Society
Medical Chair, Heart Failure and Chronic Cardiovascular Disease, CSBC
Victoria, BC, Canada

Dr. Elizabeth Swiggum is a Cardiologist, heart failure specialist and the Medical Director of the Heart Function Clinic and Cardiac Rehabilitation program at the Royal Jubilee Hospital, Victoria, B.C. since 2005. She is the Medical Chair for Heart Failure and Chronic Cardiovascular Disease at Cardiac Services BC and is Clinical Associate Professor at the University of British Columbia.

National contributions include the Canadian Cardiovascular Society Guidelines for Heart Failure and board member on the Canadian Heart Failure Society.

She has been involved in many clinical research trials related to HF including pharmacotherapy, device therapy and stem cell treatment.

Dr. Swiggum continues to advocate for prevention of cardiovascular disease through Cardiac Rehabilitation Strategic Planning.

She, herself, leads a very active life including marathon running, having completed her 12th marathon in Victoria, October 2018, winning first in her age group.

X COMPLETE BIO

Jean-François Yale

MD, CSPQ, FRCPC

Professor of Endocrinology, McGill University Health Centre, Montreal
Montreal, QC, Canada


Dr. Yale is a Professor of endocrinology at the McGill University Health Centre. Dr Yale chaired the Clinical and Scientific Section of the CDA from 1992-1994. He was a member of the Steering Committee for the Canadian Diabetes Association/Diabetes Canada Clinical Practice Guidelines from 1995 to 2019. His research interests (200 publications) include the prevention of hypoglycemia in type 1 diabetes, intensive management of type 1 and type 2 diabetes. He also participated in numerous multicentre trials on new therapies for type 1 and type 2 diabetes.


X LEARNING OBJECTIVES

After completing this module, clinicians and other healthcare professionals will be better able to:

  • Explain the relationship between diabetes and heart failure (HF)
  • Apply recently updated CCS guidelines that define new pharmacologic standards of care for HF as well as Diabetes Canada recommendations for patients with diabetes and HF
  • Safely prescribe newer diabetes agents in clinical practice
X ACCREDITATION

This event is an Accredited Self-Assessment Program under Section 3 as defined by the Royal College of Physicians & Surgeons of Canada for the Maintenance of Certification program and has been approved by the Canadian Cardiovascular Society. This program was co-developed with the Canadian Cardiovascular Society and was planned to achieve scientific integrity, objectivity, and balance. You may claim a maximum of 2 hours (credits are automatically calculated).

X DISCLOSURES

This program was made possible through an educational grant from AstraZeneca, Bayer Canada, Boehringer Ingelheim, Lilly Canada, Janssen, HLS Therapeutics Inc., Novartis & Novo Nordisk.